Study says companies spend $100 million to promote blockbuster drugs

A study by Cutting Edge Information, Driving Successful Pharma Brands: Case Studies of Real Product Launches, said companies promoting blockbuster products routinely spend over $100 million on commercialization from Phase 3 through the first year that the product is publicly available. The study said Lilly will need an aggressive campaign for Prasugrel to compete with Bristol-Myers Squibb/Sanofi-Aventis's Plavix in Europe, where the delayed-in-the-US Lilly drug won approval. 

Next Article in Pharmaceutical